272896 20241117000023.0 10.1093/neuonc/noae092 doi pmid:38835160 pmid pmc:PMC11534318 pmc 1522-8517 ISSN 1523-5866 ISSN altmetric:164222919 altmetric DZNE-2024-01308 English 610 Mynarek, Martin 0000-0003-3302-2719 0 Risk factors for domain-specific neurocognitive outcome in pediatric survivors of a brain tumor in the posterior fossa-Results of the HIT 2000 trial. Oxford 2024 Oxford Univ. Press article DRIVER Output Types/Journal article DataCite Journal Article journal journal PUB:(DE-HGF)16 1731405238_14056 PUB:(DE-HGF) ARTICLE BibTeX JOURNAL_ARTICLE ORCID Journal Article 0 EndNote Neurocognition can be severely affected in pediatric brain tumor survivors. We analyzed the association of cognitive functioning with radiotherapy dose, postoperative cerebellar mutism syndrome (pCMS), hydrocephalus, intraventricular methotrexate (MTX) application, tumor localization, and biology in pediatric survivors of a posterior fossa tumor.Subdomain-specific neurocognitive outcome data from 279 relapse-free survivors of the HIT-2000 trial (241 medulloblastoma and 38 infratentorial ependymoma) using the Neuropsychological Basic Diagnostic tool based on Cattell-Horn-Carroll's model for intelligence were analyzed.Cognitive performance 5.14 years (mean; range = 1.52-13.02) after diagnosis was significantly below normal for all subtests. Processing speed and psychomotor abilities were most affected. Influencing factors were domain-specific: CSI-dose had a strong impact on most subtests. pCMS was associated with psychomotor abilities (β = -0.25 to -0.16) and processing speed (β = -0.32). Postoperative hydrocephalus correlated with crystallized intelligence (β = -0.20) and short-term memory (β = -0.15), age with crystallized intelligence (β = 0.15) and psychomotor abilities (β = -0.16 and β = -0.17). Scores for fluid intelligence (β = -0.23), short-term memory (β = -0.17) and visual processing (β = -0.25) declined, and scores for selective attention improved (β = 0.29) with time after diagnosis.The dose of CSI was strongly associated with neurocognitive outcomes. Low psychomotor abilities and processing speed both in patients treated with and without CSI suggest a strong contribution of the tumor and its surgery on these functions. Future research therefore should analyze strategies to both reduce CSI dose and toxicity caused by other treatment modalities. 353 - Clinical and Health Care Research (POF4-353) G:(DE-HGF)POF4-353 POF4-353 POF IV 0 Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de ependymoma Other infant Other medulloblastoma Other neuropsychological late effects Other quality of survival Other Humans MeSH Child MeSH Female MeSH Male MeSH Infratentorial Neoplasms: therapy MeSH Adolescent MeSH Child, Preschool MeSH Medulloblastoma: therapy MeSH Risk Factors MeSH Ependymoma: therapy MeSH Neuropsychological Tests MeSH Cancer Survivors: psychology MeSH Cancer Survivors: statistics & numerical data MeSH Follow-Up Studies MeSH Hydrocephalus: etiology MeSH Cognition Disorders: etiology MeSH Prognosis MeSH Mutism: etiology MeSH Rossius, Anne 1 Guiard, Anika 2 Ottensmeier, Holger 3 von Hoff, Katja 4 Obrecht-Sturm, Denise 5 Bußenius, Lisa 0000-0003-3888-1360 6 Friedrich, Carsten 7 von Bueren, Andre O 0000-0003-4197-6264 8 Gerber, Nicolas U 9 Traunwieser, Thomas 10 Kortmann, Rolf-Dieter 0000-0002-8952-1819 11 Warmuth-Metz, Monika 0000-0002-3544-319X 12 Bison, Brigitte 13 Thomale, Ulrich-W 14 Krauss, Juergen 15 Pietsch, Torsten P:(DE-2719)2812617 16 dzne Clifford, Steven C 17 Pfister, Stefan M 18 Sturm, Dominik 19 Sahm, Felix 0000-0001-5441-1962 20 Tischler, Tanja 21 Rutkowski, Stefan 0000-0002-5446-9571 22 10.1093/neuonc/noae092 Vol. 26, no. 11, p. 2113 - 2124 PERI:(DE-600)2094060-9 11 2113 - 2124 Neuro-Oncology 26 2024 1522-8517 http://pub.dzne.de/record/272896/files/DZNE-2024-01308_Restricted.pdf http://pub.dzne.de/record/272896/files/DZNE-2024-01308_Restricted.pdf?subformat=pdfa pdfa oai:pub.dzne.de:272896 VDB Deutsches Zentrum für Neurodegenerative Erkrankungen I:(DE-588)1065079516 DZNE 16 P:(DE-2719)2812617 DE-HGF Gesundheit Neurodegenerative Diseases G:(DE-HGF)POF4-350 G:(DE-HGF)POF4-353 G:(DE-HGF)POF4 G:(DE-HGF)POF4-300 G:(DE-HGF)POF Clinical and Health Care Research 0 2024 Nationallizenz StatID:(DE-HGF)0420 StatID 2023-10-24 ger JCR StatID:(DE-HGF)0100 StatID NEURO-ONCOLOGY : 2022 2023-10-24 DBCoverage StatID:(DE-HGF)0200 StatID SCOPUS 2023-10-24 DBCoverage StatID:(DE-HGF)0300 StatID Medline 2023-10-24 DBCoverage StatID:(DE-HGF)0320 StatID PubMed Central 2023-10-24 DBCoverage StatID:(DE-HGF)0199 StatID Clarivate Analytics Master Journal List 2023-10-24 WoS StatID:(DE-HGF)0113 StatID Science Citation Index Expanded 2023-10-24 DBCoverage StatID:(DE-HGF)0150 StatID Web of Science Core Collection 2023-10-24 DBCoverage StatID:(DE-HGF)0160 StatID Essential Science Indicators 2023-10-24 DBCoverage StatID:(DE-HGF)1110 StatID Current Contents - Clinical Medicine 2023-10-24 IF >= 15 StatID:(DE-HGF)9915 StatID NEURO-ONCOLOGY : 2022 2023-10-24 I:(DE-2719)1011009 Brainbank (Bonn) Brainbank Unit Bonn 0 journal VDB I:(DE-2719)1011009 UNRESTRICTED